Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Solid Tumours 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 15Gemcitabine 14durvalumab 9pembrolizumab 7Oxaliplatin 6Bevacizumab 6Capecitabine 5lenvatinib 4S 1 (combination) 3Liquid Biopsy 3Irinotecan 3Folfox protocol 3Fluorouracil 3Carboplatin 3zanidatamab 2tremelimumab 2envafolimab 2Trastuzumab 2Nivolumab 2Leucovorin 2Injections 2Blood Specimen Collection 2Albumin-Bound Paclitaxel 2trastuzumab deruxtecan 1toripalimab 1tislelizumab 1poly ICLC 1niraparib 1neratinib 1larotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × brigimadlin × 90 days × Clear all
NCT05512377 2026-05-14

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Boehringer Ingelheim

Phase 2 Terminated
99 enrolled
GastrointestinalGenitourinaryThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Lung Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡